Cargando…
Phase 2, randomized, double‐blind, placebo‐controlled, 4‐week study to evaluate the safety and efficacy of OPA‐ 15406 (difamilast), a new topical selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients aged 2–14 years with atopic dermatitis
The safety and efficacy of OPA‐15406 (international non‐proprietary name, difamilast; also referred to as MM36), a new topical, selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients with atopic dermatitis aged 2–14 years were evaluated in a phase 2, randomized, double‐blind, v...
Autores principales: | Saeki, Hidehisa, Baba, Naoko, Oshiden, Kazuhide, Abe, Yuji, Tsubouchi, Hidetsugu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972691/ https://www.ncbi.nlm.nih.gov/pubmed/31713267 http://dx.doi.org/10.1111/1346-8138.15137 |
Ejemplares similares
-
Efficacy and safety of topical OPA‐15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double‐blind, placebo‐controlled study
por: Saeki, Hidehisa, et al.
Publicado: (2019) -
Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study
por: Saeki, Hidehisa, et al.
Publicado: (2022) -
Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double‐blind, vehicle‐controlled trial
por: Saeki, H., et al.
Publicado: (2021) -
Difamilast for the treatment of atopic dermatitis
por: Freitas, Egídio, et al.
Publicado: (2023) -
The Roles of Sex Hormones in the Course of Atopic Dermatitis
por: Kanda, Naoko, et al.
Publicado: (2019)